Holen Sie sich die Stockscreener-App
13.67
0.87%
-0.12
Handel nachbörslich:
13.67
Überblick
Nachrichten
Preisverlauf
Optionskette
Warum fällt RDY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$13.79
Offen:
$13.77
24-Stunden-Volumen:
1.12M
Relative Volume:
0.72
Marktkapitalisierung:
$11.41B
Einnahmen:
$3.85B
Nettoeinkommen (Verlust:
$667.93M
KGV:
20.81
EPS:
0.657
Netto-Cashflow:
$142.30M
1W Leistung:
-7.38%
1M Leistung:
-9.35%
6M Leistung:
-2.15%
1J Leistung:
-15.40%
1-Tages-Spanne:
$13.66
$13.80
1-Wochen-Bereich:
$13.66
$14.59
52-Wochen-Spanne:
$12.26
$16.89
Dr Reddys Laboratories Ltd Adr Stock (RDY) Company Profile
Vergleichen Sie RDY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RDY
Dr Reddys Laboratories Ltd Adr
|
13.67 | 11.48B | 3.85B | 667.93M | 142.30M | 0.657 |
|
ZTS
Zoetis Inc
|
146.12 | 67.59B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.20 | 45.04B | 29.98B | 958.27M | 5.31B | 0.2964 |
|
HLN
Haleon Plc Adr
|
9.29 | 42.71B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.71 | 18.00B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
304.81 | 13.24B | 2.99B | 1.21B | 1.13B | 25.06 |
Dr Reddys Laboratories Ltd Adr Stock (RDY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-05 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-12-19 | Herabstufung | Nomura | Buy → Neutral |
| 2024-01-11 | Herabstufung | Jefferies | Buy → Underperform |
| 2023-08-29 | Herabstufung | HSBC Securities | Buy → Hold |
| 2023-05-18 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2023-03-17 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-01-30 | Eingeleitet | JP Morgan | Underweight |
| 2022-11-14 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2022-01-03 | Fortgesetzt | BofA Securities | Neutral |
| 2021-07-27 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2021-02-02 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2020-09-18 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-09-18 | Hochstufung | Investec | Sell → Hold |
| 2020-01-28 | Herabstufung | CLSA | Buy → Outperform |
| 2020-01-27 | Herabstufung | CLSA | Buy → Outperform |
| 2020-01-09 | Hochstufung | Citigroup | Sell → Buy |
| 2019-11-04 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-09-04 | Hochstufung | Credit Suisse | Underperform → Outperform |
| 2019-07-01 | Hochstufung | Macquarie | Neutral → Outperform |
| 2019-06-20 | Eingeleitet | Deutsche Bank | Hold |
| 2019-06-11 | Eingeleitet | Barclays | Equal Weight |
| 2019-05-20 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-02-19 | Hochstufung | CLSA | Outperform → Buy |
| 2019-01-17 | Herabstufung | Citigroup | Neutral → Sell |
| 2017-09-21 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2017-08-31 | Hochstufung | CLSA | Underperform → Outperform |
| 2017-07-28 | Herabstufung | CLSA | Underperform → Sell |
| 2016-07-27 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2016-07-27 | Herabstufung | Jefferies | Hold → Underperform |
| 2016-02-10 | Hochstufung | Credit Agricole | Underperform → Buy |
| 2015-11-10 | Herabstufung | Citigroup | Buy → Neutral |
Alle ansehen
Dr Reddys Laboratories Ltd Adr Aktie (RDY) Neueste Nachrichten
[Latest] Global Paracetamol Market Size/Share Worth USD 1460.23 Million by 2034 at a 5.24% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - GlobeNewswire Inc.
Asian ADRs Fall As Winners And Losers Stand Out - Finimize
Trump Tariff Impact: Infosys, Wipro, HDFC Bank, Other ADR Shares Drop After US Levies 25% Tariff On India - MSN
Asian ADRs Falter On US Markets As Fintechs Slide - Finimize
NVO Stock Quote Price and Forecast - CNN
Asian Stocks Listed In The US Kicked Off The Week Lower - Finimize
Validea's Top Health Care Stocks Based On Peter Lynch7/28/2025 - Nasdaq
Asian Stocks Dipped As US-Listed ADRs Edged Lower - Finimize
Stock Picks Today: Infosys, Dr. Reddys Labs, Kajaria Ceramics, Tata Consumer Products On Brokerages Radar - NDTV Profit
Dr Reddy's Q1 Results Preview: Analysts Outlook Mixed, See Double-Digit Growth - MSN
Dr. Reddy’s Labs ADR earnings missed, revenue fell short of estimates - Investing.com Australia
India's Dr Reddy's says open to boosting U.S. manufacturing as tariff threat looms - sg.finance.yahoo.com
Asian Stocks Mixed As S&P Asia 50 ADR Index Falls - Finimize
Dr Reddys Q1 Results Preview: Analysts Outlook Mixed, See Double-Digit Growth - NDTV Profit
LLY Stock Quote Price and Forecast - CNN
HSBC Upgrades Dr. Reddy’s Laboratories Limited (RDY) to Buy from Hold - MSN
Asian ADRs Retreat As Mixed Results Hit The Market - Finimize
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
Morgan Stanley initiates coverage on Dr. Reddy’s stock with Equalweight rating - Investing.com India
Dr Reddy's Laboratories among four key stocks to trade ex-dividend today - Mint
Allspring Global Investments Holdings LLC Sells 439,622 Shares of Dr. Reddy’s Laboratories Ltd (NYSE:RDY) - Defense World
Dr. Reddys Labs, Diffusion Engineers, LMW Wheels India Dividends — Last Day To Buy - NDTV Profit
Macquarie downgrades Dr. Reddy’s stock rating to Neutral on gRevlimid concerns - Investing.com India
Mixed Movements In Asian Equities As Some Sectors Shine - Finimize
Full Truck Alliance Co. Ltd. Sponsored ADR (NYSE:YMM) Shares Acquired by Mirae Asset Global Investments Co. Ltd. - Defense World
Mather Group LLC. Buys 3,413 Shares of Haleon PLC Sponsored ADR (NYSE:HLN) - Defense World
Stock Traders Buy High Volume of VNET Group Call Options (NASDAQ:VNET) - Defense World
Dr. Reddy's Laboratories Ltd (NYSE:RDY) Stock Holdings Cut by Robeco Institutional Asset Management B.V. - MarketBeat
Asian Equities Traded in the US as ADRs Rise in Thursday Trading - 富途牛牛
Growth to continue despite macro tensions: Infosys Chairman Nandan Nilekani - Business Standard
Asian ADRs Climb With North And South Leaders - Finimize
Dr Reddy’s Breaks Past ₹1,330 Apex: SEBI RA Rajneesh Sharma Sees Trend Shift, Cautions Overbought Zone - Investing.com India
Dr Reddys Laboratories allots Equity shares - Business Standard
RDY’s Market Whiplash: 2.41% YTD Rise, 14.68% Rise in 30 Days - investchronicle.com
SBI Cards to WiproPrashanth Tapse suggests stocks to buy in the short term - Mint
Stocks Showing Rising Market Leadership: Dr. Reddy's Labs ADR Earns 81 RS Rating - Investor's Business Daily
Yatsen And Zai Lab Shine As Asian ADRs Climb In The US - Finimize
Finanzdaten der Dr Reddys Laboratories Ltd Adr-Aktie (RDY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):